Samir Chandrakant Patel
Director/Board Member at ARVO Foundation for Eye Research
Profile
Samir Chandrakant Patel was the founder of Oldtech, Inc. (founded in 2000) where he held the title of Director & Chief Medical Officer from 2000 to 2012.
He was also the founder of IVERIC bio, Inc. (founded in 2007) where he held the title of Vice Chairman & President from 2013 to 2017.
Dr. Patel's current job is at ARVO Foundation for Eye Research, where he holds the title of Member-Governors Board since 2013.
Dr. Patel's former jobs include positions at Kiora Pharmaceuticals, Inc. as a Director, Mimetogen Pharmaceuticals, Inc. as a Director, Aerie Pharmaceuticals, Inc. as a Member-Scientific Advisory Board, and The University of Chicago as an Associate Professor-Ophthalmology from 2012 to 2013.
Dr. Patel's education includes an undergraduate degree from Boston University and a doctorate degree from the University of Massachusetts Medical School.
Samir Chandrakant Patel active positions
| Companies | Position | Start |
|---|---|---|
| ARVO Foundation for Eye Research | Director/Board Member | - |
Former positions of Samir Chandrakant Patel
| Companies | Position | End |
|---|---|---|
| IVERIC BIO, INC. | Founder | 2017-01-12 |
| KIORA PHARMACEUTICALS, INC. | Director/Board Member | - |
| AERIE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Mimetogen Pharmaceuticals, Inc.
 Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Director/Board Member | - |
Oldtech, Inc.
 Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Founder | - |
Training of Samir Chandrakant Patel
| Boston University | Undergraduate Degree |
| UMass Chan Medical School | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| KIORA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 5 |
|---|---|
IVERIC bio, Inc.
 IVERIC bio, Inc. Pharmaceuticals: GenericHealth Technology IVERIC bio, Inc. operates as a biopharmaceutical company. The firm engages in discovering, developing and commercializing novel therapeutics to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. Its product candidates include Zimura and Gene Therapy. The company was founded by David R. Guyer and Samir Chandrakant Patel on January 5, 2007 and is headquartered in Parsippany, NJ. | Health Technology |
Oldtech, Inc.
Oldtech, Inc. BiotechnologyHealth Technology Oldtech, Inc. was engaged in developing treatments for conditions that affect the back of the eye, including age related macular degeneration (AMD) and diabetic macular edema (DME). The company was headquartered in New York. | Health Technology |
Mimetogen Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Mimetogen Pharmaceuticals, Inc. develops peptidomimetic small molecule drugs against glaucoma and cancer. Its product mimic the effects of neurotrophin proteins that help to maintain the health and growth of cells and tissues found in the eye. Mimetogen provides tyrosine kinase agonists that prevent neuronal death; small molecule tyrosine kinase receptor agonists, which stimulates mucin secretion from conunctival goblet cells; and small molecule neurotrophin mimetics that rescues retinal pigment epithelial cells from oxidative stress-induced apoptosis. The company was founded by Garth Cumberlidge and H. Uri Saragovi in 2005 and is headquartered in Montreal, Canada. | Health Technology |
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
| ARVO Foundation for Eye Research |
- Stock Market
- Insiders
- Samir Chandrakant Patel
